01Approach to the Critical Patient/attcp50

Immediate stabilization

›Time-critical threats requiring immediate action

›Hemodynamic collapse — suggests rupture, tamponade, or severe aortic regurgitation

›Two large-bore IV access immediately

›Resuscitation bay activation

›Airway compromise from tracheal or bronchial compression

›Immediate anesthesia or critical care consultation

›Prepare for emergent intubation

›Acute neurological deficit with chest or back pain

›Simultaneous aortic imaging and neurology consultation

›Spinal cord ischemia protocol if paraplegia or paraparesis

›Hemoptysis or hematemesis

›Aortobronchial or aortoesophageal fistula until proven otherwise

›Emergent cardiothoracic surgery activation

Hemodynamic goals

›Anti-impulse therapy targets

›Heart rate target 60–80 beats/min

›Beta-blockade is first-line (Class I recommendation, 2022 ACC/AHA)

›Rate control reduces aortic wall shear stress and dP/dt

›Systolic blood pressure target <120 mmHg

›MAP target <80 mmHg for acute aortic syndrome presentations

›Arterial line for continuous beat-to-beat monitoring

›Bilateral arm blood pressures at presentation

›Differential >20 mmHg is high-risk finding suggesting dissection

›Use higher reading for titration reference

Monitoring and escalation

›Monitoring bundle

›Continuous cardiac monitoring

02History/hx85

Symptom characterization

›Pain onset and quality

›Abrupt onset of severe chest, back, or interscapular pain

›Tearing or ripping quality highly specific for acute aortic syndrome

›Maximal at onset distinguishes from ACS

›Abdominal pain in thoracoabdominal aneurysms

›May radiate to flank or groin

›Absence of pain does not exclude TAA

›Most TAAs are asymptomatic and discovered incidentally

›Prevalence of asymptomatic TAA approximately 4.2% in population

›Compressive symptoms

›Hoarseness

›Recurrent laryngeal nerve compression by aortic arch or descending aorta

›Dysphagia

›Esophageal compression by large aneurysm

›Dyspnea or stridor

›Tracheal or bronchial compression

›Facial or arm edema

›Superior vena cava compression

Associated symptoms

›Cardiovascular symptoms

›Syncope

›May indicate carotid involvement or cardiac tamponade

›Aortic regurgitation with hemodynamic compromise

›Exertional dyspnea

›Aortic regurgitation from root dilation

›Palpitations

›Arrhythmia from cardiac compression

›Neurological symptoms

›Focal weakness or numbness

›Stroke from carotid or innominate artery involvement

›Paraplegia or paraparesis from spinal cord ischemia

›Visual changes

›Aortic arch involvement affecting cerebral perfusion

›Malperfusion symptoms

›Limb weakness, pain, or pallor

›Branch vessel malperfusion

›Oliguria or hematuria

›Renal artery malperfusion

›Abdominal pain and diarrhea

›Mesenteric malperfusion

Risk factors

›Cardiovascular risk factors

›Hypertension

›Most common comorbidity — present in >80% of TAA patients

›Chronic pressure overload promotes medial degeneration

›Smoking

›Accelerates aneurysm growth and increases dissection risk

›Hypercholesterolemia and atherosclerosis

›Particularly relevant to descending aortic involvement

›Male sex

›Approximately 70% of TAA in men

›Women have 3x higher risk of dissection or rupture at smaller diameters

›Structural and genetic risk factors

›Bicuspid aortic valve

›Associated with ascending aortic dilation independent of valve function

›Connective tissue disorders

›Marfan syndrome — FBN1 mutation, root dilation predominant

›Loeys-Dietz syndrome — TGFBR1/2 mutations, aggressive growth

›Vascular Ehlers-Danlos — COL3A1 mutation, rupture risk even at small size

›Turner syndrome — bicuspid valve and aortic coarctation association

›Familial thoracic aortic aneurysm and dissection syndrome

›Present in 13–19% of non-syndromic TAA patients

›Autosomal dominant inheritance in majority

›Inflammatory and other risk factors

›Inflammatory vasculitis

›Takayasu arteritis, giant cell arteritis, Behçet disease

›Cocaine or stimulant use

›Associated with dissection even in otherwise low-risk patients

›Prior cardiac or aortic surgery

›Increases risk of dissection and residual aortopathy

›Pregnancy and coarctation of the aorta

›Polycystic kidney disease as additional risk factor

Triggers and exposures

›Acute precipitants

›Heavy lifting or Valsalva maneuver

›Transient pressure spikes in vulnerable aortic segment

›Deceleration injury or trauma

›Aortic isthmus is common traumatic rupture site

›Cocaine or methamphetamine use

›Acute sympathomimetic surges in BP and HR

›Sudden emotional stress or exertion

Family history

›Heritable aortic disease screening

›First-degree relatives with TAA, dissection, or unexplained sudden death

›Warrants genetic assessment of patient and relatives

›Known genetic syndromes in family members

›Bicuspid aortic valve, Marfan, Loeys-Dietz

›Age at onset in affected relatives

›Earlier onset suggests higher-penetrance mutation

03Physical Exam/exam66

Vital signs

›Blood pressure assessment

›Bilateral arm measurements

›SBP differential >20 mmHg — high-risk finding for dissection

›Use higher reading for antihypertensive titration

›Lower extremity blood pressure

›Significant gradient from arms suggests thoracoabdominal involvement

›Heart rate

›Tachycardia increases aortic wall stress

›Bradycardia may indicate vagal response to severe pain

›Hemodynamic status

›Hypotension or shock

›Suggests rupture, tamponade, or severe AR

›SBP <90 mmHg requires immediate stabilization

›Pulse pressure

›Wide pulse pressure suggests significant aortic regurgitation

›Narrow pulse pressure suggests tamponade or cardiogenic shock

Cardiovascular examination

›Auscultation

›New diastolic murmur

›Aortic regurgitation from root dilation or dissection flap extending to annulus

›Early decrescendo diastolic murmur at left sternal border

›Pericardial friction rub

›Hemopericardium from contained rupture or aortitis

›Muffled heart sounds

›Pericardial tamponade

›Peripheral pulse examination

›Pulse deficit in any extremity

04Differential Diagnosis/ddx48

Acute aortic syndromes

›Aortic dissection (ICD-10: I71.0x)

›Most feared complication of TAA and primary mimic

›Stanford Type A involves ascending aorta — surgical emergency

›Stanford Type B involves descending aorta distal to left subclavian

›DeBakey classification

›Type I — entire aorta

›Type II — ascending only

›Type III — descending only

›Differentiating from TAA: intimal flap on imaging, malperfusion features

›Intramural hematoma (ICD-10: I71.0x)

›Part of acute aortic syndrome spectrum

›No intimal tear but blood within aortic wall

›Managed similarly to dissection based on location

›Crescent-shaped high-density wall thickening on non-contrast CT

›Penetrating aortic ulcer (ICD-10: I70.0)

›Atherosclerotic plaque eroding through intima

›Most common in descending thoracic aorta

›Can progress to IMH, dissection, or rupture

Cardiovascular emergencies

›Acute coronary syndrome (ICD-10: I20–I22)

›Chest pain overlap; ECG changes and troponin help differentiate

›TAA/dissection can cause inferior STEMI via right coronary ostial involvement

›Thrombolytics dangerous if aortic dissection missed

›Pulmonary embolism (ICD-10: I26.x)

›Acute dyspnea, pleuritic pain, tachycardia

›D-dimer and CTA pulmonary angiography differentiate

›Pre-test probability scoring (Wells, PERC) guides workup

05Laboratory Tests/lt50

Essential initial labs

›Complete blood count

›Hemoglobin and hematocrit

›Anemia suggests contained leak or chronic blood loss

›Baseline for surgical planning

›Leukocytosis

›Infectious aortitis or inflammatory vasculitis

›Stress leukocytosis with acute rupture

›Thrombocytopenia

›DIC in acute rupture

›Comprehensive metabolic panel

›Renal function (creatinine and BUN)

›Acute kidney injury signals renal malperfusion

›Baseline before contrast administration

›Liver enzymes

›Hepatic malperfusion in thoracoabdominal involvement

›Glucose

›Diabetic patients at higher cardiovascular risk

›Coagulation studies

›PT/INR and aPTT

›Baseline before surgical intervention

›Coagulopathy indicates DIC in acute rupture

›D-dimer

›Elevated in acute dissection and intramural hematoma

›Sensitivity 97% for acute aortic dissection at cutoff 0.5 mcg/ml

›Not specific — also elevated in PE, DVT, ACS

Cardiac biomarkers

›Troponin I or T

06Diagnostic Tests/dt85

Scoring Systems

›ADD-RS (Aortic Dissection Detection Risk Score)

›Three-item clinical decision rule for acute aortic dissection risk stratification

›High-risk condition: Marfan syndrome or other aortic disease

›High-risk pain feature: abrupt onset, severe, tearing or ripping quality

›High-risk exam feature: pulse deficit, SBP differential, or focal neurological deficit

›Scoring interpretation

›Score 0: low risk — D-dimer <0.5 mcg/ml may allow imaging deferral

›Score 1–3: intermediate to high risk — CT angiography mandatory

›Sensitivity 95.7% for acute aortic dissection when combined with D-dimer

›2010 ACCF/AHA Guideline — Class I recommendation for systematic risk stratification

›Modified ADD-RS with D-dimer

›Score 0 plus D-dimer <0.5 mcg/ml — negative predictive value 99.6%

›Can defer CT if both criteria met in low-risk patients

›Adopted in ESC 2014 algorithm (Level B recommendation)

MRI

›Cardiac MRI for TAA evaluation

›Indications

›Surveillance of aortic root and ascending aorta without radiation

›Connective tissue disease follow-up (Marfan, Loeys-Dietz)

›Renal insufficiency where iodinated contrast is contraindicated

›Characterization of aortic wall pathology — IMH, aortitis, penetrating ulcer

›Performance characteristics

›Sensitivity and specificity >95% for aortic disease characterization

›Superior soft tissue contrast for wall pathology versus CT

›4D flow MRI quantifies aortic flow and wall stress

›Limitations

›Not suitable for acute presentations — time-consuming (30–60 minutes)

›Contraindicated with certain metallic implants

›Artifact from metallic surgical clips or stents

›Protocol

›ECG-gated cine SSFP sequences for root and ascending measurements

›Contrast-enhanced MRA for full aortic extent

CT

›CT angiography of the thoracic aorta

›First-line imaging for suspected symptomatic TAA or acute aortic syndrome

›Sensitivity and specificity approaching 100% for aortic dissection

›Defines aneurysm extent, diameter, and branch vessel involvement

›ACEP Level B recommendation

›Protocol

›Non-contrast phase: identifies IMH (crescent hyperdensity), calcification

›Arterial phase: true and false lumen, intimal flap, branch vessel perfusion

›Delayed phase: slow flow in false lumen, endoleak post-TEVAR

›Surgical threshold guidance (2022 ACC/AHA)

›Ascending aorta or sinus of Valsalva: repair at >=5.5 cm

›Marfan or Loeys-Dietz: repair at >=4.5–5.0 cm

›Bicuspid aortic valve: repair at >=5.5 cm (4.5–5.0 cm with risk factors)

›Descending aorta: TEVAR at >=6.0 cm or symptomatic

›Rapid growth: surgery if growth >0.5 cm/year regardless of absolute size

›Aortic size index (ASI)

›Aortic diameter (cm) divided by body surface area (m2)

›ASI >=4.25 cm/m2 associated with significantly elevated event risk

›Useful in small-statured patients with relatively large aortas

›Limitations

›Radiation exposure — consider cumulative dose in young patients

›Contrast nephropathy risk in pre-existing renal disease

Ultrasound

›Transthoracic echocardiography (TTE)

›Initial bedside evaluation of aortic root and proximal ascending aorta

›Aortic root dilation, aortic regurgitation severity, pericardial effusion

›Left ventricular function assessment

›Performance characteristics

›Sensitivity 59–85% for proximal dissection (operator-dependent)

›Specificity 63–96%

›Inadequate for descending aorta visualization

›FAST-equivalent for aortic emergencies

›Pericardial effusion identification

›LV function and regional wall motion abnormalities

›Endorsed by ASE/EACVI multimodality imaging guidelines (2015)

›Transesophageal echocardiography (TEE)

›Superior visualization of thoracic aorta when CT unavailable or contraindicated

›Sensitivity 97–99% for aortic dissection

›Specificity 77–97%

›Advantages over CT

›No radiation or contrast requirement

›Real-time hemodynamic assessment

›Aortic valve and pericardium assessment simultaneously

›Limitations

›Blind spot: distal ascending and proximal arch (tracheal air column)

›Requires sedation and airway management in unstable patients

›Operator-dependent

›ACEP Level B: equivalent to CT angiography when CT unavailable

›Point-of-care ultrasound (POCUS)

›Rapid assessment in resuscitation bay

›Parasternal long axis: aortic root diameter measurement

›Subxiphoid view: pericardial effusion and tamponade

›Aortic root >4 cm on POCUS warrants urgent formal imaging

›Cannot exclude dissection or rule out descending aneurysm

›Confirmatory CT or TEE required in all suspected cases

07Disposition/dispo41

Surgical and ICU indications

›Emergent operative indications

›Rupture or impending rupture

›Active hemorrhage or contained rupture on imaging

›Hemodynamic instability despite resuscitation

›Type A dissection with TAA

›Immediate cardiothoracic surgery regardless of presentation time

›Malperfusion syndrome

›Limb, mesenteric, renal, or spinal malperfusion

›Rapidly expanding symptomatic aneurysm

›Escalating pain with imaging evidence of growth

›ICU admission criteria

›All symptomatic TAA presentations

›Requires continuous BP monitoring and anti-impulse therapy titration

›Aneurysm at or above surgical threshold

›Pending urgent surgical consultation and repair planning

›Hemodynamic instability

›IV antihypertensive infusion titration

›TAA meeting surgical threshold requiring urgent or emergent repair

Observation indications

›Monitored bed admission

›New or worsening symptoms in patient with known TAA pending definitive imaging

›Pain control and BP optimization while awaiting CT

›Borderline surgical threshold aneurysm with concerning features

›Accelerated growth rate documented on serial imaging

›Symptomatic even if below traditional surgical diameter threshold

Discharge criteria

›Requirements for safe discharge

08Treatment/t82

Immediate anti-impulse therapy

›Beta-blockade — first-line (Class I recommendation, 2022 ACC/AHA)

›Esmolol IV — preferred for acute titration

›Loading dose: 500 mcg/kg IV bolus over 1 minute

›Maintenance infusion: 50 mcg/kg/minute

›Titration: increase 25–50 mcg/kg/minute every 5–15 minutes

›Maximum: 300 mcg/kg/minute

›Advantage: ultra-short acting (half-life 9 minutes), easily reversed

›Labetalol IV — combined alpha and beta blockade

›Initial dose: 20 mg IV bolus over 2 minutes

›Repeat boluses of 40–80 mg every 10 minutes

›Maximum total bolus dose: 300 mg

›Infusion: 1–2 mg/minute, titrate to HR and BP targets

›Metoprolol IV — alternative if esmolol or labetalol unavailable

›5 mg IV every 5 minutes, up to 15 mg total

›Transition to oral metoprolol succinate once stable

›Heart rate target: 60–80 beats/min before adding vasodilators

›Vasodilator monotherapy without beta-blockade contraindicated

›Reflex tachycardia from vasodilation increases aortic wall stress

Adjunct antihypertensive therapy

›Vasodilators — only after adequate beta-blockade established

›Nicardipine IV — calcium channel blocker

›Initial: 5 mg/hour IV infusion

›Titration: increase 2.5 mg/hour every 5–15 minutes

›Maximum: 15 mg/hour

›Dihydropyridine — does not slow heart rate (beta-blockade essential first)

›Sodium nitroprusside IV — reserved for refractory hypertension

›Initial: 0.25–0.5 mcg/kg/minute

›Titration: increase by 0.5 mcg/kg/minute every 5 minutes

›Maximum: 10 mcg/kg/minute (cyanide toxicity risk beyond 24–72 hours)

›Requires beta-blockade to prevent reflex tachycardia

›Hydralazine and dihydralazine — avoid

›Unpredictable effect, reflex tachycardia, increases aortic stress

Pain management

›Opioid analgesia — preferred for acute aortic pain

›Morphine sulfate IV

›2–4 mg IV every 5–10 minutes titrated to pain relief

›Also reduces sympathetic activation and BP

›Hydromorphone IV — alternative

›0.2–0.4 mg IV every 10–15 minutes if morphine contraindicated

›Non-opioid analgesics

›Acetaminophen 1 g IV or oral every 6 hours as adjunct

›NSAIDs — avoid in acute setting (platelet effects, renal risk)

Surgical intervention

›Open surgical repair — ascending aorta and arch

›Cardiopulmonary bypass required

›Deep hypothermic circulatory arrest for arch replacement

›30-day operative mortality 2–5% at experienced centers

›Indications (2022 ACC/AHA)

›Ascending aorta >=5.5 cm (Class I)

›Connective tissue disease: >=4.5–5.0 cm (Class I)

›Rapid growth: >0.5 cm/year (Class IIa)

›Symptomatic regardless of size (Class I)

›Spinal cord protection strategies

›Cerebrospinal fluid drainage for thoracoabdominal cases

›Cooling and motor-evoked potential monitoring

›Thoracic endovascular aortic repair (TEVAR) — descending aorta

›Stent graft deployment via femoral artery access

›30-day mortality 2–5% vs 5–8% for open repair (SVS 2021 guideline)

›Spinal cord ischemia 5–10% — CSF drainage reduces risk

›Indications (SVS 2021 Clinical Practice Guideline)

›Descending TAA >=6.0 cm (Class I)

›Symptomatic descending TAA regardless of size (Class I)

›Anatomic eligibility: adequate proximal and distal landing zones

›Surveillance post-TEVAR

›CT at 1 month, 12 months, then annually

›Endoleak classification and treatment planning

Long-term medical therapy

›Antihypertensive agents

›ACE inhibitors or ARBs

›Losartan particularly beneficial in Marfan syndrome patients

›Reduce TGF-beta signaling implicated in medial degeneration

›Target SBP <130 mmHg for outpatient management

›Beta-blockers

›Metoprolol succinate 50–200 mg orally daily

›Propranolol 20–40 mg orally three times daily as alternative

›Long-term heart rate and BP control reduces growth rate

›Statin therapy

›High-intensity statin (atorvastatin 40–80 mg daily)

›LDL target <1.8 mmol/l in atherosclerotic TAA

›Anti-inflammatory and pleiotropic aortic wall effects

›Risk factor modification

›Smoking cessation — single most modifiable risk factor

›Reduces growth rate and event risk

›Physical activity restrictions

›Avoid isometric exercises, heavy lifting, competitive contact sports

›Aerobic activity at moderate intensity generally permitted

09Special Populations/sp86

Pregnancy

›Physiologic changes increasing aortic risk

›Plasma volume expansion increases cardiac output 30–50%

›Peak aortic stress in third trimester and peripartum period

›Hormonal changes alter aortic wall composition

›Estrogen and relaxin reduce collagen and elastin cross-linking

›Progesterone effects on smooth muscle further weaken wall integrity

›Risk amplification in connective tissue disease

›Marfan syndrome: highest risk if root >=4.0 cm

›Loeys-Dietz: high risk even with root <4.0 cm

›Preconception counseling

›Aortic root <4.0 cm — pregnancy generally safe with close monitoring

›Monthly echocardiography throughout pregnancy

›Root 4.0–4.5 cm — individualized risk discussion

›Prophylactic surgery consideration before conception

›Root >4.5 cm — surgical repair before pregnancy recommended

›Class I recommendation (2022 ACC/AHA)

›Management during pregnancy

›Beta-blockers — safe throughout pregnancy

›Metoprolol 50–100 mg orally twice daily preferred

›Monitor for fetal bradycardia and intrauterine growth restriction

›Avoid ACE inhibitors and ARBs — teratogenic (Class D)

›First trimester contraindicated; nephrotoxicity in second/third trimesters

›Imaging

›Echocardiography — no radiation, first-line surveillance

›MRI without gadolinium — safe if echocardiography inadequate

›CT angiography only if acute aortic emergency — radiation risk accepted

›Delivery planning

›Vaginal delivery generally preferred if aortic root <4.0 cm

›Cesarean section for root >=4.5 cm or hemodynamic compromise

›Epidural anesthesia for labor — reduces sympathetic BP surges

Geriatric

›Age-related considerations

›Higher baseline aneurysm prevalence in elderly patients

›Mean age of diagnosis approximately 65 years

›Degenerative medial cystic degeneration predominant mechanism

›Comorbidity burden affects surgical risk

›COPD, renal impairment, coronary artery disease common

›Frailty assessment (CFS or FRAIL scale) guides repair decisions

›Modified surgical thresholds

›Smaller repair threshold in some elderly patients

›Life expectancy and operative risk must be weighed

›Aneurysm-related death probability vs. surgical mortality

›TEVAR preferred over open repair when anatomically feasible

›Lower operative mortality in high-risk elderly patients

›30-day mortality benefit maintained at 2 years

›Medication considerations in elderly patients

›Renal clearance reduction — dose-adjust ACE inhibitors and ARBs

›Monitor creatinine and potassium after initiation

›Beta-blocker tolerance

›Bradycardia and hypotension more likely

›Start at lowest dose and titrate slowly

›Fall risk with antihypertensive therapy

›Orthostatic hypotension screening

›SBP target may be relaxed to 130–140 mmHg in frail elderly

›Cognitive considerations

›Informed consent capacity assessment

›Surrogate decision-maker identification if needed

›Post-operative cognitive dysfunction risk with cardiopulmonary bypass

›Higher risk in elderly patients undergoing open repair

Pediatrics

›Pediatric TAA — rare; primarily genetic aortopathy

›Common etiologies in children

›Marfan syndrome — FBN1 mutation; ascending root dilation from birth

›Loeys-Dietz syndrome — early aggressive course, multiple arterial aneurysms

›Congenital aortic stenosis with post-stenotic dilation

›Kawasaki disease — coronary and aortic involvement

›Turner syndrome in adolescent females

›Bicuspid aortic valve and aortic coarctation association

›Weight-based and age-appropriate thresholds

›Aortic Z-scores used instead of absolute diameter

›Z-score >2 standard deviations above mean for body surface area

›Z-score >3–4 triggers intervention consideration in most centers

›Marfan surgical threshold in children

›Root >=4.0–4.5 cm or Z-score >3–4 (individualized)

›Rate of growth >0.5 cm/year is independent indication

›Pediatric medication dosing

›Beta-blockers

›Atenolol 0.5–1 mg/kg/day orally once daily (max 2 mg/kg/day)

›Propranolol 0.5–1 mg/kg/day in 2–3 divided doses (max 4 mg/kg/day)

›Target resting HR <100 beats/min or 25% reduction from baseline

›Losartan in Marfan syndrome

›0.4–0.6 mg/kg/day orally once daily (max 50 mg/day)

›COMPARE trial: non-inferior to atenolol for root growth rate

›ACE inhibitors — avoid in neonates; use with caution in children

›Genetic counseling referral

›All pediatric TAA patients warrant genetic assessment

›Familial testing of first-degree relatives

›Cascade screening program for syndromic aortopathy

10Background/b96

Epidemiology

›Prevalence and incidence

›Population prevalence approximately 4.2% for thoracic aortic dilation

›TAA constitutes a small subset of all aortic aneurysms

›Abdominal aortic aneurysm is more common (4:1 ratio vs TAA)

›Incidence 5–10 per 100,000 person-years

›Rising due to increased CT utilization and aging population

›KP-TAA Study (JAMA Cardiology 2022): large population cohort analysis

›Anatomic distribution

›Ascending aorta or aortic root: approximately 60% of TAAs

›Most often associated with bicuspid aortic valve or Marfan syndrome

›Aortic arch: approximately 10%

›Often contiguous with ascending or descending segment

›Descending thoracic aorta: approximately 30%

›Most often atherosclerotic; associated with smoking and hypertension

›Demographics

›Male predominance — approximately 70% of cases

›Women present at older age but with higher event risk at smaller sizes

›Mean age of diagnosis approximately 65 years for degenerative TAA

›Genetic aortopathy presents decades earlier

›Familial TAA — 13–19% of non-syndromic patients have affected relatives

›Complications and outcomes

›Annual risk of rupture or dissection increases exponentially with diameter

›5 cm: annual risk approximately 6%

›6 cm: annual risk approximately 15%

›>7 cm: annual risk >25% per year

›Rupture mortality exceeds 50% including pre-hospital deaths

›Growth rate

›Degenerative TAA: approximately 1–2 mm/year

›Marfan syndrome: up to 2–3 mm/year

›Loeys-Dietz: most rapid growth of genetic aortopathies

Pathophysiology

›Medial degeneration — common final pathway

›Cystic medial degeneration (Erdheim disease)

›Loss of smooth muscle cells and elastic fiber fragmentation

›Accumulation of mucopolysaccharide matrix in aortic media

›Predominantly affects ascending aorta

›Molecular mechanisms

›Matrix metalloproteinase (MMP-2, MMP-9) upregulation

›TGF-beta signaling dysregulation in connective tissue syndromes

›Reactive oxygen species from hypertension and atherosclerosis

›Hemodynamic mechanisms

›Law of Laplace — wall tension proportional to radius x pressure

›Larger aneurysm diameter amplifies wall stress for given blood pressure

›Explains accelerating growth rate and rupture risk with increasing size

›dP/dt (rate of pressure rise) — key driver of aortic stress

›Beta-blockade targets dP/dt reduction as primary therapeutic mechanism

›Turbulent flow within aneurysm sac

›Intraluminal thrombus formation common in large aneurysms

›Thromboembolism risk from mural thrombus

›Genetic mechanisms

›Marfan syndrome (FBN1 mutation)

›Fibrillin-1 deficiency disrupts extracellular matrix scaffolding

›Excessive TGF-beta activity drives cystic medial degeneration

›Loeys-Dietz syndrome (TGFBR1/2, SMAD3 mutations)

›TGF-beta receptor pathway dysfunction

›Aggressive course: aneurysms at multiple sites, high dissection risk

›Vascular Ehlers-Danlos (COL3A1 mutation)

›Type III collagen deficiency

›Rupture risk even at small aortic diameters (<5 cm)

›Bicuspid aortic valve

›Intrinsic medial abnormality independent of altered flow

›Coexists with NOTCH1 and other signaling pathway variants

›Atherosclerotic mechanism

›Intimal atherosclerosis erodes medial support

›Inflammatory infiltrate (T-cells, macrophages) degrades extracellular matrix

›Predominantly affects descending thoracic and thoracoabdominal aorta

›Shared risk factors: smoking, hypertension, hyperlipidemia, male sex

Therapeutic Considerations

›Pharmacological evidence base

›Beta-blockers — strongest evidence in Marfan syndrome

›Shores et al. (1994) RCT: propranolol reduced aortic growth rate in Marfan

›Extrapolated to all TAA by 2010 and 2022 ACC/AHA guidelines

›Class I recommendation for anti-impulse therapy in acute presentations

›ARBs in genetic aortopathy

›Losartan reduces TGF-beta signaling

›COMPARE trial (2013): losartan non-inferior to atenolol in Marfan syndrome

›Benefit in non-Marfan TAA less well established

›Statins

›Anti-inflammatory pleiotropic effects on aortic wall

›Observational data suggest slowed growth in descending TAA

›No RCT evidence specifically for TAA growth reduction

›Surgical timing controversies

›TITAN: SvS RCT (2025, J Thorac Cardiovasc Surg)

›Explored non-diameter indices (aortic size index, height index)

›Non-diameter indices may identify surgical candidates missed by diameter alone

›Conservative diameter thresholds may miss high-risk small aneurysms

›Women at equivalent risk at 4.5–5.0 cm compared to men at 5.5 cm

›Body surface area indexing (ASI) improves threshold accuracy

›Elective vs. urgent repair timing

›30-day mortality 2–5% elective vs. 15–20% emergent for ascending repair

›Strong argument for elective intervention once threshold reached

›Endovascular versus open repair evidence

›TEVAR for descending TAA

›SVS 2021 guideline favors TEVAR over open when anatomically feasible

›Lower 30-day mortality (2–5% TEVAR vs. 5–8% open)

›Higher late reintervention rate — endoleak, stent migration, retrograde dissection

›Systematic review and prospective cohort (HTA 2022)

›Sharples et al.: TEVAR associated with lower early mortality; open repair more durable

11Patient Discharge Instructions/pdi35

copy discharge instructions

›Discharge instructions for the chart

›Diagnosis and basic explanation

›You have been diagnosed with a thoracic aortic aneurysm — an enlargement of the large artery in your chest

›This condition requires careful monitoring and blood pressure control to prevent complications

›Medications — take all medications exactly as prescribed

›Blood pressure medications: do not skip doses

›Beta-blockers: do not stop suddenly without physician guidance

›Statins: continue long-term for cardiovascular risk reduction

›Blood pressure monitoring at home

›Target blood pressure below 130/80 mmHg

›Record readings twice daily and bring log to follow-up appointments

›Activity restrictions

›Avoid heavy lifting, straining, or bearing down (Valsalva maneuver)

›No competitive or high-intensity contact sports

›Light to moderate aerobic activity (walking, swimming) is generally safe

›Discuss return to exercise with your specialist

›Lifestyle modifications

›Stop smoking immediately — this is the most important action you can take

›Limit alcohol consumption to reduce blood pressure

›Follow a heart-healthy low-sodium diet

›Avoid cocaine, methamphetamine, and stimulant drugs — they can cause rupture

›Scheduled follow-up

›Attend all imaging appointments — serial CT or MRI monitoring is essential

›If stable: imaging every 6–24 months depending on aneurysm size

›Do not miss cardiothoracic or vascular surgery appointments

›Family screening

›Inform first-degree relatives (parents, siblings, children) of your diagnosis

12References/r50

Guidelines and key sources

›2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease

›Isselbacher EM, Preventza O, Hamilton Black JJ, et al.

›Journal of the American College of Cardiology. 2022

›Comprehensive guideline covering all aspects of TAA diagnosis and management

›https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860464/

›ACR Appropriateness Criteria — Thoracic Aortic Aneurysm or Dissection (2024 Update)

›Ripley B, Scheidt MJ, Aghayev A, et al.

›Journal of the American College of Radiology. 2025

›Imaging appropriateness criteria and multimodality guidance

›https://linkinghub.elsevier.com/retrieve/pii/S1546-1440(25)00125-5

›2010 ACCF/AHA/AATS/ACR Guidelines for Thoracic Aortic Disease

›Hiratzka LF, Bakris GL, Beckman JA, et al.

›Journal of the American College of Cardiology. 2010

›Foundation guideline establishing ADD-RS and management principles

›https://pubmed.ncbi.nlm.nih.gov/20359588

›SVS Clinical Practice Guidelines — Thoracic Endovascular Aortic Repair (2021)

›Upchurch GR, Escobar GA, Azizzadeh A, et al.

›Journal of Vascular Surgery. 2021

›TEVAR indications and outcomes evidence

›https://linkinghub.elsevier.com/retrieve/pii/S0741-5214(20)31521-4

Landmark trials and reviews

›Acute Aortic Dissection and Intramural Hematoma — Systematic Review

›Mussa FF, Horton JD, Moridzadeh R, et al.

›JAMA. 2016

›D-dimer and ADD-RS performance characteristics

›https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2016.10026

›Thoracic Aortic Aneurysm — Nature Reviews Disease Primers

Evidence & Review